MiniMed vs ResMed
MMED and RMD side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MMED and RMD compare
ResMed is the larger company, worth 6.4 times as much as MiniMed ($33.2B against $5.1B).
MiniMed grew revenue faster over the last twelve months (14.3% versus 9.9% for ResMed).
ResMed keeps more of each dollar of sales as profit, with a net margin of 26.9% compared with −10.7% at MiniMed.
ResMed pays a dividend yielding 1.1%; MiniMed does not pay one.
ResMed scores higher on the StockData Score (21 against 13 for MiniMed), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MMED | RMD |
|---|---|---|
| Size and price | ||
| Market cap | $5.1B | $33.2B |
| Share price | $18.28 | $229.94 |
| Change, 1 year | – | −9.3% |
| Change, 5 years | – | −11.7% |
| Beta (5Y) | – | 0.91 |
| Employees | 8,000 | 11K |
| StockData Score | ||
| Total score | 13 | 21 (better) |
| Valuation score | 3 | 4 (better) |
| Growth score | 2 | 3 (better) |
| Performance score | 2 | 6 (better) |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | – | 22.0× |
| P/S | 1.7× (better) | 5.9× |
| P/B | 1.4× (better) | 5.0× |
| EV/EBITDA | – | 15.3× |
| P/FCF | – | 20.1× |
| PEG | – | 1.12 |
| FCF yield | −8.2% | 5.0% (better) |
| Fair value | $35.17 | $259.82 |
| Margin of safety | 48.0% (better) | 11.5% |
| Growth | ||
| Revenue growth (TTM) | 14.3% (better) | 9.9% |
| Revenue growth, 5Y average | – | 12.1% |
| Net income growth (TTM) | – | 8.8% |
| EPS growth (TTM) | – | 9.7% |
| EPS growth, 5Y average | – | 26.3% |
| Profitability | ||
| Gross margin | 54.2% | 61.1% (better) |
| Operating margin | −6.1% | 33.4% (better) |
| Net margin | −10.7% | 26.9% (better) |
| FCF margin | −13.5% | 29.2% (better) |
| Return on equity | −9.6% | 24.3% (better) |
| Return on invested capital | −4.5% | 29.5% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.04 (better) |
| Net debt / EBITDA | – | −0.58 |
| Current ratio | 1.81 | 3.10 (better) |
| Altman Z-score | 3.46 | 11.21 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 1.1% |
| Payout ratio | – | 23.0% |
| Years of dividend growth | – | 5 |
| Dividend growth, 5Y average | – | 9.0% |
| Buyback yield | – | 1.9% |
| Shareholder yield | 0.00% | 3.0% (better) |
| Ownership | ||
| Held by institutions | 13.2% | 69.4% |
| Held by insiders | 90.6% | 1.3% |
| Insider net buying, 12 months | – | −$21.1M |
| Superinvestors holding | – | 1 |
Go deeper
- MMED stock overview
- MMED income statement
- MMED valuation and score
- RMD stock overview
- RMD income statement
- RMD valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.